Results 101 to 110 of about 67,431 (260)

New Bcr-Abl-independent mechanisms of resistance to imatinib treatment in chronic myelogenous leukaemia patients

, 2008
Although rare in chronic phase myeloid leukemia (CML), primary or acquired resistance to the treatment with tyrosine kinase inhibitors (TKI) may be observed in the advanced phases of disease.
Esposito, Nicola
core  

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen, Hanadi El Achi, Levani Iashvili, Amer Wahed, Brenda Mai, Jacob Armstrong   +5 more
wiley   +1 more source

Clinical pharmacokinetics of imatinib and its therapeutic relevance

, 2013
The pharmacokinetic profile of imatinib has been assessed in healthy subjects and in population studies among thousands of patients with CML or GIST. Imatinib is rapidly and extensively absorbed from the GI tract, reaching a peak plasma concentration ...
Csajka, C., von Mehren, M., Decosterd, L.A., Widmer, N., Buclin, T., Haouala, A., Gotta, V., Blanc, J., Leyvraz, S., Duchosal, M.   +9 more
core  

Imatinib-Loaded Micelles of Hyaluronic Acid Derivatives for Potential Treatment of Neovascular Ocular Diseases

, 2018
In this work, new micellar systems able to cross corneal barrier and to improve the permeation of imatinib free base were prepared and characterized. HA-EDA-C16, HA-EDA-C16−PEG, and HA-EDA-C16−CRN micelles were synthesized starting from hyaluronic acid ...
Giovanna Pitarresi (2376100), Calogero Fiorica, Giulia Di Prima, Calogero Fiorica (1877362), Fabio S. Palumbo, Gaetano Giammona, Giovanna Pitarresi, Fabio S. Palumbo (3758338), Gaetano Giammona (1422994), Flavia Bongiovì (5818652), Fabio Salvatore Palumbo, Giulia Di Prima (5818655), Flavia Bongiovì   +12 more
core   +1 more source

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

, 2005
The BCR-ABL tyrosine kinase inhibitor imatinib has greatly improved the outcome for patients with chronic myeloid leukaemia (CML). Unfortunately, mutations causing resistance to imatinib are leading to relapses in some patients. In addition to inhibiting
Doggrell, Sheila A., Doggrell, Sheila
core   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting

International Journal of Nanomedicine, 2014
Peng Ye,1,2 Wendian Zhang,1 Tan Yang,1 Yao Lu,1 Miao Lu,1 Yongkang Gai,1 Xiang Ma,1 Guangya Xiang1 1School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of ...
Ye P, Zhang W, Yang T, Lu Y, Lu M, Gai Y, Ma X, Xiang G   +7 more
doaj  

Cytogenetic Diversity of Variant Philadelphia Translocations in Chronic Myeloid Leukemia

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Chronic myeloid leukemia (CML) is a disease characterized by Philadelphia (Ph) translocations. These translocations can be classical or variant. The structural features and diagnostic implications of variant Philadelphia translocations remain incompletely defined, and they display considerable cytogenetic heterogeneity. Methods In
Ayse Gul Bayrak Tokac, Aynur Aday, Simge Erdem, Gulcin Bagatir, Burak Don, Ozden Ozcan, Akif Selim Yavuz, Sevgi Kalayoglu Besisik, Meliha Nalcaci, Kivanc Cefle, Sukru Ozturk   +10 more
wiley   +1 more source

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments

, 2019
Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib-resistance of chronic myeloid leukemia (CML) remains elusive.
Yanhong, Tan, Jie, Xiong, Lianrong, Xu, Hongwei, Wang, Xiuhua, Chen, Mengxia, Zhu, Liqin, Yao, Yan, Zhao, Yan, Liu, Jiangfang, Feng, Fanggang, Ren, Fei, Pan   +11 more
core   +1 more source

Force profiles of imatinib dissociation from imatinib-c-Kit complex.

, 2013
(A) Force profile of imatinib unbinding along traditional ATP-channel. (B) Force profile of imatinib unbinding along allosteric-pocket-channel. (C) Averaged force profiles of imatinib unbinding along ATP-channel (red) and allosteric-pocket-channel (black)
Jun Zou (683), Huan-Zhang Xie (368262), Sheng-Yong Yang (192164), Li-Jun Yang (368261), Lin-Li Li (192153), Yu-Quan Wei (192158)   +5 more
core   +1 more source